- Home
- CGEN vs LPTX Comparison
CGEN vs LPTX Comparison
Compare CGEN & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- LPTX
- Stock Information
- Founded
- CGEN 1993
- LPTX 2011
- Country
- CGEN Israel
- LPTX United States
- Employees
- CGEN N/A
- LPTX N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGEN Health Care
- LPTX Health Care
- Exchange
- CGEN Nasdaq
- LPTX Nasdaq
- Market Cap
- CGEN N/A
- LPTX 119.6M
- IPO Year
- CGEN 2000
- LPTX N/A
- Fundamental
- Price
- CGEN $1.27
- LPTX $0.37
- Analyst Decision
- CGEN Strong Buy
- LPTX Buy
- Analyst Count
- CGEN 1
- LPTX 2
- Target Price
- CGEN $4.00
- LPTX $8.00
- AVG Volume (30 Days)
- CGEN 200.0K
- LPTX 381.5K
- Earning Date
- CGEN 05-19-2025
- LPTX 05-20-2025
- Dividend Yield
- CGEN N/A
- LPTX N/A
- EPS Growth
- CGEN N/A
- LPTX N/A
- EPS
- CGEN N/A
- LPTX N/A
- Revenue
- CGEN $27,864,000.00
- LPTX N/A
- Revenue This Year
- CGEN $11.81
- LPTX N/A
- Revenue Next Year
- CGEN $28.37
- LPTX N/A
- P/E Ratio
- CGEN N/A
- LPTX N/A
- Revenue Growth
- CGEN N/A
- LPTX N/A
- 52 Week Low
- CGEN $1.13
- LPTX $0.22
- 52 Week High
- CGEN $2.66
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- CGEN 44.34
- LPTX 46.49
- Support Level
- CGEN $1.23
- LPTX $0.33
- Resistance Level
- CGEN $1.52
- LPTX $0.38
- Average True Range (ATR)
- CGEN 0.08
- LPTX 0.03
- MACD
- CGEN -0.01
- LPTX 0.00
- Stochastic Oscillator
- CGEN 27.89
- LPTX 43.64
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .